Athos Therapeutics and Xeptiva Therapeutics have announced a strategic partnership to leverage AthosOmics.AI, a cutting-edge AI-powered platform, to discover vaccine biomarkers for Xeptiva’s lead experimental therapeutic vaccine targeting chronic pain in dogs with osteoarthritis. Under the collaboration, Xeptiva will provide plasma samples collected from clinical trial participants—canines treated with its proprietary osteoarthritis vaccine candidate. These samples will be analyzed using proteomic data processed through the AthosOmics.AI platform, which is designed to rapidly identify novel and actionable protein biomarkers associated with treatment response. The partnership marks a first-of-its-kind application of AI-driven omics analysis in the life sciences industry, combining clinical trial data with advanced machine learning to accelerate biomarker discovery. AthosOmics.AI is a no-code, agentic AI platform capable of analyzing raw or pre-processed omics data—including genomics, transcriptomics, and proteomics—without requiring specialized bioinformatics or computational expertise. The platform automates complex workflows, delivering clear, actionable insights quickly and cost-effectively. Dimitrios Iliopoulos, PhD, MBA, Founder, President, and CEO of Athos Therapeutics, emphasized the platform’s transformative potential. “We are excited to use AthosOmics.AI to support Xeptiva’s precision medicine veterinary programs by harnessing AI to uncover prognostic and predictive biomarker signatures unique to their vaccine approach,” he said. “While the platform has already been clinically validated for our internal drug discovery and biomarker development, AthosOmics.AI is now ready to empower innovation across industries generating omics data.” Josefina Correa, MS, Founder, President, and CEO of Xeptiva, highlighted the importance of innovation in veterinary medicine. “Xeptiva is committed to developing first-in-class therapeutic vaccines for companion animals, and AthosOmics.AI gives us the ability to rapidly and comprehensively identify biomarkers linked to our therapeutic strategies,” she said. Athos Therapeutics is a clinical-stage biotech company focused on developing precision small molecule therapeutics for immune-mediated diseases. Its lead candidate, ATH-063, is an oral small molecule for inflammatory bowel disease entering Phase 2 clinical trials. The AthosOmics.AI platform integrates multi-omic and longitudinal clinical data from over 35,000 patient samples sourced from leading global hospitals. It enables end-to-end drug discovery—from identifying protein targets and designing small molecules based on 3D protein structures to evaluating ADME and safety profiles. The platform’s capabilities extend beyond pharmaceuticals into agriculture, forensics, food and beverage, and cosmetics, offering a versatile, one-stop solution for omics data analysis. For more information, visit https://www.athosomics.ai/en/home. Xeptiva Therapeutics, founded in 2021 after a decade of research in chronic neuroinflammation, is developing first-in-class therapeutic vaccines for chronic inflammatory conditions in pets. The company is currently running efficacy trials for its lead candidates targeting osteoarthritis-related pain and atopic dermatitis, aiming to deliver long-term, affordable, and effective immunotherapies for companion animals. For more information, visit https://www.xeptiva.com/ and https://athostx.com/. Media and investor inquiries: Athos Therapeutics, Inc. – Keith Hoffman, PhD, Chief Business Officer, [email protected] Xeptiva Therapeutics – Josefina Correa, MS, Chief Executive Officer, [email protected]